Cabaletta Bio, Inc. (CABA)

Current Report Filed: 2026-03-23

Cabaletta Bio reported its Q4 2025 and full-year 2025 financial results, providing investors with an update on the company's financial performance and operational progress.
The company posted an updated corporate presentation, which likely contains new information on its pipeline, milestones, and strategic initiatives that investors should review.
Investors should monitor any potential changes in Cabaletta's leadership team or key personnel, as management transitions can impact a company's direction and execution.

Annual Report Filed: 2026-03-23

Cabaletta Bio, Inc. (CABA) appears to be a clinical-stage biotechnology company focused on the development of novel T cell therapies for autoimmune diseases. The company has several licensing agreements and strategic partnerships, indicating potential collaborations and growth opportunities.
The 10-K filing highlights Cabaletta's ongoing research and development activities, with a focus on its lead product candidate for pemphigus vulgaris. This suggests the company is making progress in advancing its pipeline.
The company reported an increase in general and administrative expenses, which could indicate the need for additional funding or the expansion of its operations. Investors should monitor the company's cash position and financing activities.

Insider Trading Filed: 2026-01-21

Michael Gerard, the General Counsel of Cabaletta Bio, Inc. (CABA), purchased 6,600 shares of the company's common stock on January 21, 2026 at a weighted average price of $2.2696 per share.
This insider buying activity may signal Gerard's confidence in the company's future prospects and could be viewed positively by investors.
The transaction amount is relatively small, suggesting it may not be a significant event, but it still provides insight into the company's leadership's perspective on the stock's valuation.

Insider Trading Filed: 2026-01-21

Insider Mark Simon purchased 11,061 shares of Cabaletta Bio, Inc. (CABA) at an average price of $2.2838, increasing his direct ownership to 147,205 shares.
Simon also owns an additional 7,000 shares indirectly through his spouse, indicating a sizable and growing personal stake in the company.
The insider purchase suggests Simon's confidence in Cabaletta Bio's prospects and aligns his interests with those of other shareholders.

Insider Trading Filed: 2026-01-21

The reporting person, Steven Nichtberger, who is the President and CEO of Cabaletta Bio, Inc., has directly acquired 45,000 shares of the company's common stock at a weighted average price of $2.2395 per share.
Nichtberger also holds an indirect beneficial ownership of 363,000 shares through the 2017 Nichtberger Family Trust.
This insider buying activity could be a positive signal for investors, as the CEO is demonstrating confidence in the company's prospects by increasing his personal stake.

Insider Trading Filed: 2026-01-21

Catherine Bollard, a director of Cabaletta Bio, Inc., acquired 4,405 shares of the company's common stock on January 21, 2026 at a price of $2.2661 per share.
This purchase increases Bollard's direct beneficial ownership to 5,405 shares of Cabaletta's common stock.
Insider buying, especially by directors, can be a positive signal about the company's prospects and potential future performance.

Insider Trading Filed: 2026-01-21

Steve Gavel, the Chief Commercial Officer of Cabaletta Bio, Inc. (CABA), has directly purchased 22,170 shares of the company's common stock on January 21, 2026 at a weighted average price of $2.265 per share.
This insider buying activity suggests that Gavel has confidence in the company's future prospects and is willing to invest his own capital in the stock.
The purchase of a sizable number of shares by a key executive could signal positive sentiment within the company and may be viewed favorably by investors.

Insider Trading Filed: 2026-01-21

Insider Shawn Tomasello acquired 22,725 shares of Cabaletta Bio, Inc. (CABA) at $2.2144 per share, indicating his confidence in the company's prospects.
The transaction represents a direct ownership increase for Tomasello, further aligning his interests with those of other shareholders.
Insider buying of this magnitude can be viewed as a positive signal, as insiders typically have superior information about the company's future performance.

Insider Trading Filed: 2026-01-21

Insider Gwendolyn Binder, the President of Science and Technology, purchased 11,312 shares of Cabaletta Bio, Inc. (CABA) at $2.1891 per share, indicating confidence in the company's prospects.
This insider purchase represents a direct ownership increase of 56.4% for Binder, signaling a positive view on the company's future performance.
Insider buying is often seen as a positive signal, as it suggests the reporting person believes the stock is undervalued and has potential for future growth.

Insider Trading Filed: 2026-01-21

The reporting person, David J. Chang, the Chief Medical Officer of Cabaletta Bio, Inc., has acquired 8,800 shares of the company's common stock at a price of $2.26 per share.
This purchase suggests that the insider has a positive outlook on the company's future prospects and is willing to increase their ownership stake.
The timing of the transaction, which occurred on January 21, 2026, may indicate the insider's confidence in the company's near-term performance or upcoming events.

Current Report Filed: 2026-01-12

Cabaletta Bio has initiated a registrational cohort for its rese-cel therapy in dermatomyositis and antisynthetase syndrome, which affects about 70,000 patients in the US, with the potential to submit a Biologics License Application next year.
The company has aligned with the FDA on registrational cohort designs for evaluating rese-cel in systemic lupus erythematosus and lupus nephritis, with updates expected later this year.
Cabaletta is advancing its fully automated, scalable manufacturing for rese-cel using Cellares' Cell Shuttle and Cell Q technology, which could enable rapid global expansion and lower manufacturing costs post-commercialization.

Important Information